Sun Pharma Launches Taro-Methylphenidate ER for ADHD
Mumbai, India and Brampton, Ontario, Canada, September 21, 2026 Sun Pharmaceutical Industries Limited (Sun Pharma) has announced the commercial...
Attention Deficit Hyperactivity Disorder
Advertisement
Tris Pharma Expands QuilliChew ER With 30-Count Bottle
MONMOUTH JUNCTION, N.J. — September 14, 2026 Tris Pharma, Inc. announced the availability of a new 30-count bottle size...
Otsuka’s SIMTRIYO® Becomes First Approved NDSRI for ADHD
PRINCETON, N.J., July 27, 2026 Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) have announced...
Otsuka Wins FDA Approval for First-in-Class SIMTRIYO for ADHD
PRINCETON, N.J. and TOKYO, Japan, July 24, 2026 Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd....
Otsuka Reports Positive Phase 3b Results for Centanafadine
TOKYO, Japan & PRINCETON, N.J., June 26, 2026 Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc....
Advertisement
